Update on the management of hypertension in 2023

Authors

  • Doreen M. Rabi, MD, MSc, FRCPC O’Brien Institute for Public Health; Libin Cardiovascular Institute of Alberta; Cumming School of Medicine, University of Calgary

DOI:

https://doi.org/10.58931/cpct.2023.1212

Abstract

Hypertension is the most common condition managed in the primary care setting. It is a potent but modifiable risk factor for cardiovascular disease (CVD) and premature mortality. Currently, approximately 25% of Canadian adults have a diagnosis of hypertension. However, the global community is experiencing challenges with optimizing hypertension management; it is estimated that at least 23% of individuals globally have effectively managed hypertension. Furthermore, if clinicians were able to identify and adequately intervene in these cases, we could prevent 10.8 million deaths per year. This statistic is extremely relevant to Canadian practitioners as our most recent Canadian data suggest that 34% of adults with hypertension are not achieving target blood pressure (BP) due to undertreatment or lack of awareness.

The undertreatment of hypertension is complex. There are a number of structural and environmental drivers of CV risk, and there is increasing recognition that if we are going to be effective at CV risk reduction, we must acknowledge the significant role that social determinants play in the development of risk factors including hypertension, smoking, obesity and diabetes.

The clinical guidance concerning hypertension may inadvertently contribute to the challenges we are seeing globally with hypertension management. There are numerous guidelines available to inform clinicians about how to provide supportive care for individuals with hypertension, and discordance between guidelines and the granularity of guidelines make implementation challenging. While there is disparity between guidelines, as well as differences regarding hypertension nomenclature, there is unanimous agreement that accurate BP measurement, risk-based thresholds for intervention, simplified approaches to pharmacotherapy, and well-structured care are the foundations of effective hypertension management.

Author Biography

Doreen M. Rabi, MD, MSc, FRCPC, O’Brien Institute for Public Health; Libin Cardiovascular Institute of Alberta; Cumming School of Medicine, University of Calgary

Dr. Doreen Rabi is a Professor in Medicine and the Head of Endocrinology and Metabolism at the University of Calgary. Dr. Rabi is also a health services researcher at the Libin Cardiovascular Institute of Alberta and the O’Brien Institute for Public Health. She has received nearly $5 million in peer-reviewed research grants, has published more than 160 papers, and made significant contributions to Canadian clinical practice guidelines in hypertension and diabetes. As a professor, she spends most of her time striving for a more equitable and inclusive practice of medicine through her research, mentorship, and advocacy activities.

References

GBD 2019 Risk Factors Collaborators. Global burden of 87 risk factors in 204 countries and territories, 1990-2019: a systematic analysis for the Global Burden of Disease Study 2019. Lancet. 2020;396(10258):1223-49. DOI: https://doi.org/10.1016/S0140-6736(20)30752-2

Garies S, Hao S, McBrien K, Williamson T, Peng M, Khan NA, Padwal RS, Quan H, Leung AA. Prevalence of hypertension, treatment, and blood pressure targets in Canada associated with the 2017 American College of Cardiology and American Heart Association Blood Pressure Guidelines. JAMA Netw Open. 2019 Mar 1;2(3):e190406. DOI: https://doi.org/10.1001/jamanetworkopen.2019.0406

Leung AA, Williams JV, McAlister FA, Campbell NR, Padwal RS, Tran K, Tsuyuki R, Khan N, Padwal R, Quan H. Worsening hypertension awareness, treatment, and control rates in Canadian women between 2007 and 2017. Can J Cardiol. 2020 May 1;36(5):732-9. DOI: https://doi.org/10.1016/j.cjca.2020.02.092

NCD Risk Factor Collaboration. Worldwide trends in hypertension prevalence and progress in treatment and control from 1990 to 2019: a pooled analysis of 1201 population-representative studies with 104 million participants. Lancet. 2021;398(10304):957-80. DOI: https://doi.org/10.1016/S0140-6736(21)01330-1

Gagné T, Veenstra G. Inequalities in hypertension and diabetes in Canada: intersections between racial identity, gender, and income. Ethn Dis. 2017;27(4):371. DOI: https://doi.org/10.18865/ed.27.4.371

Whelton PK. Evolution of blood pressure clinical practice guidelines: a personal perspective. Can J Cardiol. 2019 May 1;35(5):570-81. DOI: https://doi.org/10.1016/j.cjca.2019.02.019

Alper BS, Price A, van Zuuren EJ, Fedorowicz Z, Shaughnessy AF, Oettgen P, Elwyn G, Qaseem A, Kunnamo I, Gupta U, Carter DD. Consistency of recommendations for evaluation and management of hypertension. JAMA Netw Open. 2019 Nov 1;2(11):e1915975. DOI: https://doi.org/10.1001/jamanetworkopen.2019.15975

Molino CD, Leite-Santos NC, Gabriel FC, Wainberg SK, de Vasconcelos LP, Mantovani-Silva RA, Ribeiro E, Romano-Lieber NS, Stein AT, de Melo DO. Factors associated with high-quality guidelines for the pharmacologic management of chronic diseases in primary care: a systematic review. JAMA Intern Med. 2019 Apr 1;179(4):553-60. DOI: https://doi.org/10.1001/jamainternmed.2018.7529

Al-Makki A, DiPette D, Whelton PK, Murad MH, Mustafa RA, Acharya S, Beheiry HM, Champagne B, Connell K, Cooney MT, Ezeigwe N. Hypertension pharmacological treatment in adults: a World Health Organization guideline executive summary. Hypertension. 2022 Jan;79(1):293-301. DOI: https://doi.org/10.1161/HYPERTENSIONAHA.121.18192

Sakhuja S, Jaeger BC, Akinyelure OP, Bress AP, Shimbo D, Schwartz JE, Hardy ST, Howard G, Drawz P, Muntner P. Potential impact of systematic and random errors in blood pressure measurement on the prevalence of high office blood pressure in the United States. J Clin Hypertens. 2022 Mar;24(3):263-70. DOI: https://doi.org/10.1111/jch.14418

Cheung AK, Whelton PK, Muntner P, Schutte AE, Moran AE, Williams B, Sarafidis P, Chang TI, Daskalopoulou SS, Flack JM, Jennings G. International Consensus on Standardized Clinic Blood Pressure Measurement–A Call to Action. Am J Med. 2023 Jan 6. DOI: https://doi.org/10.1016/j.amjmed.2022.12.015

Rabi DM, McBrien KA, Sapir-Pichhadze R, Nakhla M, Ahmed SB, Dumanski SM, Butalia S, Leung AA, Harris KC, Cloutier L, Zarnke KB. Hypertension Canada’s 2020 comprehensive guidelines for the prevention, diagnosis, risk assessment, and treatment of hypertension in adults and children. Can J Cardiol. 2020 May 1;36(5):596-624. DOI: https://doi.org/10.1016/j.cjca.2020.02.086

Lu Y, Linderman GC, Mahajan S, Liu Y, Huang C, Khera R, Mortazavi BJ, Spatz ES, Krumholz HM. Quantifying Blood Pressure Visit-to-Visit Variability in the Real-World Setting: A Retrospective Cohort Study. Circ Cardiovasc Qual Outcomes. 2023 Apr;16(4):e009258. DOI: https://doi.org/10.1161/CIRCOUTCOMES.122.009258

Karnjanapiboonwong A, Anothaisintawee T, Dejthevaporn C, Attia J, Thakkinstian A. Diagnostic performance of clinic and home blood pressure measurements compared with ambulatory blood pressure: a systematic review and meta-analysis. BMC Cardiovasc Disord. 2020 Dec;20(1):1-7. DOI: https://doi.org/10.1186/s12872-020-01736-2

Verdecchia P. Prognostic value of ambulatory blood pressure: current evidence and clinical implications. Hypertension. 2000 Mar;35(3):844-51. DOI: https://doi.org/10.1161/01.HYP.35.3.844

Roerecke M, Kaczorowski J, Myers MG. Comparing automated office blood pressure readings with other methods of blood pressure measurement for identifying patients with possible hypertension: a systematic review and meta-analysis. JAMA Intern Med. 2019 Mar 1;179(3):351-62. DOI: https://doi.org/10.1001/jamainternmed.2018.6551

Fagard RH, Celis H, Thijs L, Staessen JA, Clement DL, De Buyzere ML, De Bacquer DA. Daytime and nighttime blood pressure as predictors of death and cause-specific cardiovascular events in hypertension. Hypertension. 2008 Jan 1;51(1):55-61. DOI: https://doi.org/10.1161/HYPERTENSIONAHA.107.100727

O’Brien E, Parati G, Stergiou G, Asmar R, Beilin L, Bilo G, Clement D, De La Sierra A, De Leeuw P, Dolan E, Fagard R. European Society of Hypertension position paper on ambulatory blood pressure monitoring. J Hypertens. 2013 Sep 1;31(9):1731-68. DOI: https://doi.org/10.1097/HJH.0b013e328363e964

Parati G, Stergiou G, O’Brien E, Asmar R, Beilin L, Bilo G, Clement D, De La Sierra A, De Leeuw P, Dolan E, Fagard R. European Society of Hypertension practice guidelines for ambulatory blood pressure monitoring. J Hypertens. 2014 Jul 1;32(7):1359-66. DOI: https://doi.org/10.1097/HJH.0000000000000221

Unger T, Borghi C, Charchar F, Khan NA, Poulter NR, Prabhakaran D, Ramirez A, Schlaich M, Stergiou GS, Tomaszewski M, Wainford RD. 2020 International Society of Hypertension global hypertension practice guidelines. Hypertension. 2020 Jun;75(6):1334-57. DOI: https://doi.org/10.1161/HYPERTENSIONAHA.120.15026

Libianto R, Fuller PJ, Young MJ, Yang J. Primary aldosteronism is a public health issue: challenges and opportunities. J Hum Hypertens. 2020 Jul;34(7):478-86. DOI: https://doi.org/10.1038/s41371-020-0336-2

Kline GA, Prebtani AP, Leung AA, Schiffrin EL. The potential role of primary care in case detection/screening of primary aldosteronism. Am J Hypertens. 2017 Nov 6;30(12):1147-50. DOI: https://doi.org/10.1093/ajh/hpx064

Whelton PK, Carey RM, Aronow WS, Casey DE, Jr., Collins KJ, Dennison Himmelfarb C, et al. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Hypertension. 2018;71(6):e13-e115. DOI: https://doi.org/10.1161/HYP.0000000000000065

Williams B, Mancia G, Spiering W, Agabiti Rosei E, Azizi M, Burnier M, et al. 2018 ESC/ESH Guidelines for the management of arterial hypertension: The Task Force for the management of arterial hypertension of the European Society of Cardiology and the European Society of Hypertension: The Task Force for the management of arterial hypertension of the European Society of Cardiology and the European Society of Hypertension. J Hypertens. 2018;36(10):1953-2041. DOI: https://doi.org/10.1097/HJH.0000000000001940

Group SR, Wright JT, Jr., Williamson JD, Whelton PK, Snyder JK, Sink KM, et al. A Randomized Trial of Intensive versus Standard Blood-Pressure Control. N Engl J Med. 2015;373(22):2103-16. DOI: https://doi.org/10.1056/NEJMoa1511939

Manuel DG, Tuna M, Bennett C, Hennessy D, Rosella L, Sanmartin C, Tu JV, Perez R, Fisher S, Taljaard M. Development and validation of a cardiovascular disease risk-prediction model using population health surveys: the Cardiovascular Disease Population Risk Tool (CVDPoRT). CMAJ. 2018 Jul 23;190(29):E871-82. DOI: https://doi.org/10.1503/cmaj.170914

Khan N, Bacon SL, Khan S, Perlmutter S, Gerlinsky C, Dermer M, Johnson L, Alves F, McLean D, Laupacis A, Pui M. Hypertension management research priorities from patients, caregivers, and healthcare providers: A report from the Hypertension Canada Priority Setting Partnership Group. J Clin Hypertens. 2017 Nov;19(11):1063-9. DOI: https://doi.org/10.1111/jch.13091

Ettehad D, Emdin CA, Kiran A, Anderson SG, Callender T, Emberson J, Chalmers J, Rodgers A, Rahimi K. Blood pressure lowering for prevention of cardiovascular disease and death: a systematic review and meta-analysis. Lancet. 2016 Mar 5;387(10022):957-67. DOI: https://doi.org/10.1016/S0140-6736(15)01225-8

Xie X, Atkins E, Lv J, Bennett A, Neal B, Ninomiya T, Woodward M, MacMahon S, Turnbull F, Hillis GS, Chalmers J. Effects of intensive blood pressure lowering on cardiovascular and renal outcomes: updated systematic review and meta-analysis. Lancet. 2016 Jan 30;387(10017):435-43. DOI: https://doi.org/10.1016/S0140-6736(15)00805-3

Menard J. Cost-effectiveness of hypertension treatment. Clin Exp Hypertens. 1996;18(3-4):399-413. DOI: https://doi.org/10.3109/10641969609088972

Chen YJ, Li LJ, Tang WL, Song JY, Qiu R, Li Q, Xue H, Wright JM. First‐line drugs inhibiting the renin angiotensin system versus other first‐line antihypertensive drug classes for hypertension. Cochrane Database Syst Rev. 2018:11(11). DOI: https://doi.org/10.1002/14651858.CD008170.pub3

Sundström J, Lind L, Nowrouzi S, Hagström E, Held C, Lytsy P, Neal B, Marttala K, Östlund O. Heterogeneity in blood pressure response to 4 antihypertensive drugs: a randomized clinical trial. JAMA. 2023 Apr 11;329(14):1160-9. DOI: https://doi.org/10.1001/jama.2023.3322

Wald DS, Law M, Morris JK, Bestwick JP, Wald NJ. Combination therapy versus monotherapy in reducing blood pressure: meta-analysis on 11,000 participants from 42 trials. Am J Med. 2009 Mar 1;122(3):290-300. DOI: https://doi.org/10.1016/j.amjmed.2008.09.038

Weisser B, Predel HG, Gillessen A, Hacke C, vor dem Esche J, Rippin G, Noetel A, Randerath O. Single pill regimen leads to better adherence and clinical outcome in daily practice in patients suffering from hypertension and/or dyslipidemia: results of a meta-analysis. High Blood Press Cardiovasc Prev. 2020 Apr;27:157‑64. DOI: https://doi.org/10.1007/s40292-020-00370-5

Jones CP. Invited commentary:“race,” racism, and the practice of epidemiology. Am J Epidemiol. 2001 Aug 15;154(4):299-304. DOI: https://doi.org/10.1093/aje/154.4.299

Antihypertensive T, Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA. 2002 Dec 18;288(23):2981‑97. DOI: https://doi.org/10.1001/jama.288.23.2981

Flack JM, Buhnerkempe MG. Race and antihypertensive drug therapy: edging closer to a new paradigm. Hypertension. 2022 Feb;79(2):349-51. DOI: https://doi.org/10.1161/HYPERTENSIONAHA.121.18545

Campbell NR, Jeffrey P, Kiss K, Jones C, Anton AR. Building capacity for awareness and risk factor identification in the community: the blood pressure assessment program of the Calgary Fire Department. Can J Cardiol. 2001 Dec 1;17(12):1275-9.

Ye C, Foster G, Kaczorowski J, Chambers LW, Angeles R, Marzanek-Lefebvre F, Laryea S, Thabane L, Dolovich L. The impact of a cardiovascular health awareness program (CHAP) on reducing blood pressure: a prospective cohort study. BMC Public Health. 2013 Dec;13:1. DOI: https://doi.org/10.1186/1471-2458-13-1230

Alshehri AA, Jalal Z, Cheema E, Haque MS, Jenkins D, Yahyouche A. Impact of the pharmacist‐led intervention on the control of medical cardiovascular risk factors for the primary prevention of cardiovascular disease in general practice: a systematic review and meta‐analysis of randomised controlled trials. Br J Clin Pharmacol. 2020 Jan;86(1):29-38. DOI: https://doi.org/10.1111/bcp.14164

Donabedian A. The quality of care: how can it be assessed? JAMA.1988 Sep 23;260(12):1743-8. DOI: https://doi.org/10.1001/jama.260.12.1743

Tobe SW, Campbell NR, Padwal RS, Khan NA, Singer J. Change of education strategy associated with slippage in Canadian hypertension awareness treatment and control rates. J Hum Hypertens. 2021 Nov;35(11):1054-6. DOI: https://doi.org/10.1038/s41371-021-00519-2

Daskalopoulou SS, Feldman RD, McAlister FA, Rabi DM, Hypertension C. The History of Hypertension Guidelines in Canada. Can J Cardiol. 2019;35(5):582-9. DOI: https://doi.org/10.1016/j.cjca.2019.01.017

Published

2023-06-14

How to Cite

1.
Rabi DM. Update on the management of hypertension in 2023. Can Prim Care Today [Internet]. 2023 Jun. 14 [cited 2024 Feb. 29];1(2):5–10. Available from: https://canadianprimarycaretoday.com/article/view/1-2-rabi

Issue

Section

Articles